Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
January 18, 2017 06:45 ET
|
CoLucid Pharmaceuticals, Inc
$960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 ...
CoLucid Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 28, 2016 13:58 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...
CoLucid Pharmaceuticals Provides SPARTAN Enrollment Update
November 14, 2016 08:00 ET
|
CoLucid Pharmaceuticals, Inc
Comparison of 50 mg, 100 mg and 200 mg of lasmiditan oral tablets to placebo for the acute treatment of migraineOver 50% of the expected 2,968 migraine patients enrolled77% of patients enrolled to...
CoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights
November 09, 2016 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the quarter ended September 30, 2016. ...
CoLucid Pharmaceuticals to Present at the Stifel 2016 Healthcare Conference
November 08, 2016 08:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...
CoLucid Pharmaceuticals Announces Additional Analyses of Lasmiditan’s Onset of Action Data from SAMURAI and Supporting Non-Clinical Data
October 05, 2016 10:54 ET
|
CoLucid Pharmaceuticals, Inc
Lasmiditan (100 mg and 200 mg) oral tablets had onset of action and provided significant headache pain relief as soon as 30 minutes after dosing (p ≤ 0.004) and freedom from the most bothersome...
CoLucid Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
September 26, 2016 07:00 ET
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of...
CORRECTING and REPLACING – CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR
September 19, 2016 10:43 ET
|
CoLucid Pharmaceuticals, Inc
1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively have been administered over 7,500 times in GLADIATOR...
CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR
September 19, 2016 07:00 ET
|
CoLucid Pharmaceuticals, Inc
1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively have been administered over 7,500 times in GLADIATOR...
CoLucid Pharmaceuticals Announces Achievement of Secondary Endpoints in SAMURAI
September 17, 2016 05:30 ET
|
CoLucid Pharmaceuticals, Inc
100 mg and 200 mg doses of lasmiditan were more efficacious than placebo on headache pain relief at the two-hour time point (p < 0.001)100 mg and 200 mg doses of lasmiditan were more efficacious...